Zoetis Parasiticides — Revenue increased by 8.1% to $586.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.3%, from $562.00M to $586.00M. Over 4 years (FY 2021 to FY 2025), Parasiticides — Revenue shows an upward trend with a 9.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests strong demand for preventative animal health care and successful market adoption of the product portfolio, while a decrease may indicate increased competition, patent expirations, or shifts in pet owner spending habits.
This metric represents the total net sales generated from the sale of pharmaceutical products designed to prevent or tre...
Comparable to animal health segments focused on preventative medicine or specialty pharmaceutical portfolios at major veterinary health competitors.
zts_segment_parasiticides_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $460.00M | $396.00M | $389.00M | $459.00M | $536.00M | $422.00M | $443.00M | $432.00M | $568.00M | $465.00M | $482.00M | $504.00M | $600.00M | $530.00M | $519.00M | $562.00M | $673.00M | $564.00M | $542.00M | $586.00M |
| QoQ Change | — | -13.9% | -1.8% | +18.0% | +16.8% | -21.3% | +5.0% | -2.5% | +31.5% | -18.1% | +3.7% | +4.6% | +19.0% | -11.7% | -2.1% | +8.3% | +19.8% | -16.2% | -3.9% | +8.1% |
| YoY Change | — | — | — | — | +16.5% | +6.6% | +13.9% | -5.9% | +6.0% | +10.2% | +8.8% | +16.7% | +5.6% | +14.0% | +7.7% | +11.5% | +12.2% | +6.4% | +4.4% | +4.3% |